27 Sep 2022 15:08
Yourgene Health plc
("Yourgene", the "Company" or the "Group")
Result of AGM
Manchester, UK - 27 September 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that at the Annual General Meeting held earlier today, all resolutions were passed.
The voting results are now available on the 'Shareholder Communications' section of the Company's website: https://www.yourgene-health.com/investors/key-documents/shareholder-communications
Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 investors@yourgene-health.com |
Barry Hextall, Chief Financial Officer |
|
Joanne Cross, Director of Marketing |
|
|
|
Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 |
Liam Murray / James Caithie / Ludovico Lazzaretti |
|
|
|
Singer Capital Markets (Corporate Broker) | Tel: +44 (0)20 7496 3000 |
Aubrey Powell / Tom Salvesen / George Tzimas |
|
|
|
Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com |
Paul McManus / Lianne Applegarth / Alice Woodings
| Mob: 07980 541 893 / 07584 391 303 / 07407 804 654
|
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The Yourgene Genomic Services team works with healthcare professionals, researchers and pharmaceutical organisations to support and accelerate scientific advances in genomic medicine. The division's specialist services guide decisions about abnormalities, hereditary risk and treatment in addition to providing novel insights in research and discovery. Accredited clinical services are provided in Oncology and Reproductive Health within the UK and worldwide. The team of scientific experts offer consultative services to help guide partners in selecting the right technology and approach for their applications.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.